Arrowhead Pharmaceuticals
ARWR
61.48
-0.06
-0.10%
Arrowhead Pharmaceuticals
US · ARWR
#1569 by market cap
Listed 1970
61.48
-0.06
-0.10%
Live - 5344 symbols - heartbeat 439s ago
· 2026-10-08 07:06
Pre-market
60.60
-1.43%
After-hours
61.48
0.00%
Overnight
61.48
0.00%
- Market cap
- 8.68B
- P/E (TTM)i
- -26.96
- P/Bi
- 18.65
- EPSi
- -0.01
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on ARWR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.75, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +23,258.15% YoY
Margins
- Operating margin
- 11.86%
- Net margin
- -0.20%
Key ratios & quality
- Enterprise valuei
- 8.03B
- Altman Z-Scorei
- 5.75
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.14M | 168.80M | 87.99M | 138.29M | 243.23M | 240.74M | 3.55M | 829.45M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 19.11M | 26.56M | 52.28M | 80.98M | 124.43M | 90.93M | 96.82M | 121.92M |
| Research & development | 52.97M | 81.05M | 128.88M | 206.34M | 297.31M | 353.19M | 505.87M | 607.16M |
| Operating profit | -55.94M | 61.19M | -93.16M | -149.04M | -178.51M | -205.00M | -601.08M | 98.35M |
| Pretax profit | -54.45M | 68.15M | -84.55M | -140.85M | -172.71M | -206.49M | -612.46M | 51.53M |
| Tax | 2.40K | 174.00K | 2.00K | 2.00K | 3.79M | 2.78M | -2.77M | 21.42M |
| Net profit | -54.45M | 67.98M | -84.55M | -140.85M | -176.49M | -209.28M | -609.69M | 30.11M |
| Basic EPS | -1 | 1 | -1 | -1 | -2 | -2 | -5 | 0 |
| Diluted EPS | -0.65 | 0.69 | -0.84 | -1.36 | -1.67 | -1.92 | -5.00 | -0.01 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 542.71M | 27.77M | 256.47M | 264.03M | 73.74M | 75.25M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 27.89M | 30.44M | 37.18M | 45.52M | 41.24M | 46.63M |
| Research & development | 133.10M | 162.37M | 174.69M | 177.20M | 173.25M | 198.22M |
| Operating profit | 381.20M | -165.55M | 44.11M | 40.81M | -141.26M | -170.09M |
| Pretax profit | 369.62M | -179.09M | 36.12M | 28.27M | -137.57M | -178.91M |
| Tax | 1.75M | -437.00K | 20.00M | 29.00K | 7.00K | 11.00K |
| Net profit | 367.86M | -178.65M | 16.12M | 28.24M | -137.57M | -178.92M |
| Basic EPS | 3 | -1 | 0 | 0 | -1 | -1 |
| Diluted EPS | 2.75 | -1.26 | -0.18 | 0.22 | -0.93 | -1.36 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 78.77M | 265.25M | 322.37M | 384.60M | 405.30M | 416.47M | 695.47M | 950.64M |
| Cash & ST investments | 76.53M | 258.70M | 315.49M | 367.79M | 376.40M | 403.63M | 680.96M | 919.37M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 111.61M | 349.85M | 522.50M | 710.15M | 691.94M | 765.55M | 1.14B | 1.39B |
| Total current liabilities | 12.36M | 97.07M | 40.68M | 146.54M | 138.85M | 105.46M | 103.17M | 195.49M |
| Short-term debt | 223.82K | -- | 1.10M | 2.25M | 2.78M | 10.56M | 6.34M | 47.29M |
| Long-term debt | 2.10M | -- | -- | -- | -- | -- | 393.18M | 214.88M |
| Total liabilities | 16,368,950.00 | 105,809,185.00 | 60,725,000.00 | 301,326,000.00 | 273,600,000.00 | 478,390,000.00 | 948,739,000.00 | 881,879,000.00 |
| Total equity | 95.24M | 244.04M | 461.78M | 408.82M | 418.34M | 287.16M | 191.06M | 503.42M |
| Retained earnings | -487.27M | -419.29M | -503.84M | -644.69M | -820.76M | -1.03B | -1.63B | -1.63B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.14B | 946.92M | 950.64M | 1.17B | 1.84B | 1.67B |
| Cash & ST investments | 1.10B | 900.37M | 919.37M | 916.61M | 1.78B | 1.60B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.57B | 1.38B | 1.39B | 1.60B | 2.27B | 2.11B |
| Total current liabilities | 220.54M | 194.53M | 195.49M | 347.43M | 295.22M | 283.35M |
| Short-term debt | 71.78M | 47.01M | 47.29M | 47.53M | 47.77M | 45.32M |
| Long-term debt | 208.93M | 200.33M | 214.88M | 163.11M | 841.58M | 824.07M |
| Total liabilities | 889,273,000.00 | 860,806,000.00 | 881,879,000.00 | 1,041,484,000.00 | 1,669,349,000.00 | 1,645,972,000.00 |
| Total equity | 684.23M | 519.81M | 503.42M | 562.70M | 598.92M | 466.04M |
| Retained earnings | -1.43B | -1.60B | -1.63B | -1.60B | -1.73B | -1.92B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -47.22M | 173.04M | -95.80M | 171.31M | -136.13M | -153.89M | -462.85M | 179.55M |
| Depreciation & amortization | 4.70M | 4.44M | 5.94M | 8.27M | 10.42M | 12.49M | 18.60M | 23.93M |
| Free cash flow | -48.64M | 161.03M | -107.75M | 147.75M | -188.91M | -330.63M | -604.32M | 156.89M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 56.59M | 60.52M | 250.48M | -- | 0 | 0 | 429.27M | 241.39M |
| Ending cash balance | 30.13M | 221.80M | 143.58M | 184.43M | 108.01M | 110.89M | 102.69M | 226.55M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 460.05M | -154.72M | 20.49M | 13.48M | 84.44M | -177.47M |
| Depreciation & amortization | 6.08M | 6.22M | 6.39M | 6.39M | 6.37M | 6.66M |
| Free cash flow | 454.76M | -157.08M | 13.00M | 11.33M | 81.88M | -181.32M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 241.39M | 0 | 0 | 46.83M | 1.32M | 27.95M |
| Ending cash balance | 185.71M | 129.79M | 226.55M | 201.64M | 188.52M | 54.76M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -61.45 | 39.94 | -23.94 | -32.36 | -43.62 | -61.29 | -262.48 | -0.50 |
| ROA %i | -50.50 | 29.46 | -19.39 | -22.85 | -25.11 | -28.17 | -62.93 | -0.13 |
| ROIC %i | -59.81 | 39.94 | -22.59 | -30.71 | -38.51 | -46.82 | -108.99 | 5.17 |
| 5-year avg ROE %i | -61.32 | -41.25 | -32.75 | -23.33 | -24.28 | -24.25 | -84.74 | -80.05 |
| EBIT margin %i | -346.52 | 36.25 | -105.87 | -107.77 | -73.39 | -78.16 | -16,336.47 | 16.99 |
| FCF / sales %i | -- | 95.40 | -- | 106.78 | -- | -- | -- | 18.91 |
| Current ratioi | 6.37 | 2.73 | 7.92 | 2.62 | 2.92 | 3.95 | 6.74 | 4.86 |
| Quick ratioi | 6.22 | 2.67 | 7.78 | 2.58 | 2.72 | 3.83 | 6.60 | 4.74 |
| Debt / assetsi | 2.08 | 0.00 | 4.05 | 3.60 | 11.79 | 15.04 | 44.79 | 26.44 |
| LT debt / equityi | 2.19 | -- | 4.34 | 5.70 | 19.77 | 38.55 | 271.89 | 68.45 |
| Interest coveragei | -- | -- | -- | -- | -- | -10.27 | -17.93 | 1.58 |
| Revenue CAGR (3Y) %i | 248.31 | 921.56 | 40.97 | 104.62 | 12.95 | 39.86 | -70.50 | 50.52 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -24.67 | -34.80 | -0.50 | 65.14 | -46.39 | -64.78 |
| ROA %i | -11.39 | -13.11 | -0.13 | 15.45 | -15.67 | -18.32 |
| ROIC %i | -14.16 | -16.82 | 5.17 | 34.11 | -20.44 | -25.46 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -16.37 | -13.10 | 16.99 | 31.64 | -25.70 | -23.82 |
| FCF / sales %i | 1.76 | -- | 18.91 | 29.52 | -- | -- |
| Current ratioi | 5.15 | 4.87 | 4.86 | 3.38 | 6.23 | 5.90 |
| Quick ratioi | 4.99 | 4.68 | 4.74 | 3.27 | 6.10 | 5.68 |
| Debt / assetsi | 24.67 | 25.57 | 26.44 | 19.50 | 43.62 | 46.58 |
| LT debt / equityi | 46.31 | 58.59 | 68.45 | 46.66 | 153.37 | 201.57 |
| Interest coveragei | -1.42 | -0.91 | 1.58 | 3.83 | -1.73 | -1.72 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovery, development, manufacturing and commercialization of RNA interference (RNAi) therapeutics100.00%
Quote time 2026-10-08 07:06:10 · For reference only, not investment advice and not tailored to your situation.